Clinical observation of “Zifei Sanjie Decoction” in preventing castrate resistant prostate cancer

YAO Quan-bao; PEN Yu; ZENG Li-qiong; GU Wei; MAO Wen-juan; ZHOU Yong-ming; NIU Yi-jun

您当前的位置：

首页 >

文章列表页 >

Clinical observation of “Zifei Sanjie Decoction” in preventing castrate resistant prostate cancer

更新时间：2022-08-31

- Clinical observation of “Zifei Sanjie Decoction” in preventing castrate resistant prostate cancer
- Shanghai Journal of Traditional Chinese Medicine Vol. 50, Issue 8, Pages: 49-51(2016)
- 作者机构：
  
  1. 上海交通大学附属第一人民医院分院中医科,上海,200081
  2. 上海中医药大学附属岳阳中西医结合医院泌尿科,上海,200437
- 作者简介：
- 基金信息：
- DOI：
  CLC：
扫描看全文
YAO Quan-bao, PEN Yu, ZENG Li-qiong, et al. Clinical observation of “Zifei Sanjie Decoction” in preventing castrate resistant prostate cancer. [J]. Shanghai Journal of Traditional Chinese Medicine 50(8):49-51(2016)
DOI：

YAO Quan-bao, PEN Yu, ZENG Li-qiong, et al. Clinical observation of “Zifei Sanjie Decoction” in preventing castrate resistant prostate cancer. [J]. Shanghai Journal of Traditional Chinese Medicine 50(8):49-51(2016) DOI：

摘要

目的：观察滋肺散结方对去势抵抗型前列腺癌(CRPC)的预防作用。方法：将110例非去势抵抗型前列腺癌患者随机分为对照组与治疗组,每组55例。对照组予去势加内分泌治疗,治疗组在对照组治疗措施基础上,加服滋肺散结方治疗。两组疗程均为3个月,随访至终点时间或研究截止,观察去势抵抗发生率、血尿与骨转移发生率、终点事件发生率,比较前列腺特异性抗原(PSA)的倍增情况。结果：①至2016年3月,110例病例的随访时间范围为12~36个月,中位随访时间为24个月。②至研究截止时,治疗组、对照组CRPC发生率分别为10.91%、69.09%,差异有统计学意义,治疗组明显低于对照组(P<0.05)。两组PSA倍增情况比较,差异有统计学意义,治疗组明显低于对照组(P<0.05)。③两组血尿与骨转移发生率比较,差异有统计学意义,即治疗组明显低于对照组(P<0.05)。④两组终点事件发生率比较,差异有统计学意义,即治疗组明显低于对照组(P<0.05)。结论：滋肺散结方可一定程度上抑制CRPC的发生,减少尿血及骨转移,从而提高患者生活质量,延长其生存时间。

Abstract

Objective:To observe the preventive effects of “Zifei Sanjie Decoction” on castrate resistant prostate cancer(CRPC). MethodsTotal 110 subjects with non-CRPC were randomized into two group:the control group in which 55 cases were treated with castration and endocrine therapy,and the treatment group in which 55 cases were treated with “Zifei Sanjie Decoction” additionally, with a course of 3 months. At the end of follow up, the incidence of castration resistance, hematuria and bone metastases, and terminal events were observed, the doubling of prostate specific antigen (PSA) was compared. Results:①Up to March 2016,the follow up time for all patients ranged from 12~36 months. Median time was 24 months. ②The incidence of CRPC in the treatment group and control group were 10.91% and 69.09% respectively, the difference was statistically significant, and the treatment group was significantly lower than that of the control group (P<0.05). ③There were statistically significant differences in the doubling of PSA,hematuria and bone metastases and terminal events between two groups,and those in treatment group was significantly lower than the control group (P<0.05). Conclusion:“Zifei Sanjie Decoction” could inhibit the CRPC to a certain extent and decrease the hematuria and bone metastasis, which improve the life quality of patients and prolong the survival time.

关键词

前列腺癌去势抵抗型滋肺散结方骨转移预防性治疗

Keywords

prostatic cancertype of castration resistant“Zifei Sanjie Decoction”bone metastasispreventive treatment

references

Views

107

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical study on Sanjie Tongluo Granule combined with western medicine in treating bone metastases of malignant tumor

Regulation of Gutongling Decoction on MAPK signaling pathway in spinal cord of bone metastasis mice

Clinical research of “Gutongling Decoction” in relieving pain due to bone metastatic pulmonary cancer

Related Author

No data

Related Institution

The Second Department of Oncology， Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai

Shanghai Yangpu Hospital of Traditional Chinese Medicine Shanghai

⁰